Is Sermorelin Legal in Washington? How to Access It Legally

The Short Answer on Legality

Sermorelin is legal to prescribe, compound, and possess in Washington State when the full legal chain is intact. That chain has three links: a licensed prescriber who issues a valid patient-specific prescription, a compliant 503A compounding pharmacy that fills it, and a patient who obtains the drug through that prescription. Break any one of those links and the activity falls outside the law.

Washington has no state statute that singles out sermorelin for restriction. The controlling legal framework is federal, built on the Food, Drug and Cosmetic Act, FDA guidance on compounded drugs, and DEA scheduling rules.

Federal Status: Not Scheduled, Not Approved for Adults

The DEA does not list sermorelin as a controlled substance under the Controlled Substances Act. You can confirm this by searching the DEA Diversion Control Division's list of scheduled substances. Sermorelin is a synthetic 29-amino-acid peptide analog of endogenous growth hormone-releasing hormone (GHRH). Possession without a prescription is not a federal criminal offense the way possession of, say, testosterone cypionate would be, because testosterone is Schedule III.

The FDA approved the branded product Geref (sermorelin acetate for injection, Serono Laboratories) in 1997 specifically for the treatment of idiopathic growth hormone deficiency (GHD) in children. That approval was withdrawn by the manufacturer in 2008 for commercial reasons, not for safety findings. The FDA's approval withdrawal letter does not constitute a ban on compounding sermorelin; it simply means no currently marketed finished drug product holds an NDA for sermorelin. [1]

Why the Lack of FDA Approval Matters for Compounders

Under Section 503A of the Federal Food, Drug and Cosmetic Act, a compounding pharmacy may prepare a drug that is not commercially available so long as it is compounded in response to a valid patient-specific prescription. Because no finished FDA-approved sermorelin product is currently on the market for adults, a 503A pharmacy can compound it without violating the "essentially a copy" prohibition that applies when a commercial product exists. [2]

Section 503B outsourcing facilities operate under different rules. The FDA's bulk-drug substances lists for 503B facilities (Category 1, "nominated with sufficient support," and Category 2, "nominated without sufficient support") determine what 503B facilities can legally compound without a prescription. As of mid-2025, sermorelin does not appear on the Category 1 list for 503B facilities, which means 503B outsourcing facilities cannot legally compound sermorelin for office-stock dispensing. [3] This is a meaningful limitation: it means your sermorelin must come from a 503A pharmacy filling your individual prescription, not from a large-scale outsourcer shipping bulk vials to a clinic.

Washington State Pharmacy Law and Compounding

Washington State does not layer additional restrictions on sermorelin beyond what federal law requires. The Washington State Pharmacy Quality Assurance Commission (PQAC) enforces sterile compounding under USP <797> standards, which govern microbial contamination limits, beyond-use dating, and environmental monitoring for any sterile injectable preparation. [4]

What 503A Means in Practice for Washington Patients

A 503A pharmacy in Washington (or one licensed to ship into Washington) must:

• Receive a patient-specific prescription from a Washington-licensed prescriber.
• Compound sermorelin in a cleanroom meeting USP <797> standards.
• Label the vial with the patient's name, prescriber's name, dispensing date, beyond-use date, and dosage instructions.
• Not advertise or mass-produce the compound in advance of receiving prescriptions.

The beyond-use date for a compounded sterile sermorelin preparation is typically 45 to 90 days under refrigeration, depending on the pharmacy's validated stability data. Patients should verify their pharmacy's specific beyond-use dating.

Washington Telehealth Parity and Prescribing

Washington's telehealth parity law (RCW 74.09.325) requires that health plans cover telehealth services on the same basis as in-person services. This means a Washington-licensed clinician can legally conduct a telehealth evaluation, assess labs, and prescribe sermorelin without ever seeing a patient face-to-face, provided the prescribing meets standard-of-care documentation requirements. [5] The prescription is valid under both Washington Medical Commission rules and federal law.

Who Can Prescribe Sermorelin in Washington

Any Washington-licensed clinician with prescribing authority can write a sermorelin prescription. That includes MDs, DOs, naturopathic physicians (NDs, who hold prescriptive authority in Washington under RCW 18.36A.060), and physician assistants or ARNPs with appropriate supervision or independent practice arrangements.

Standard of Care for Prescribing

The Washington Medical Commission does not publish a specific sermorelin prescribing protocol, but the standard-of-care expectation follows general off-label prescribing principles: the clinician must have a documented clinical rationale, informed consent must be obtained, and the patient record must reflect the prescribing decision. Most clinicians who prescribe sermorelin for adult GHD or age-related GH decline order a baseline IGF-1 level, a comprehensive metabolic panel, and often a GHRH-arginine stimulation test or insulin tolerance test before initiating therapy. [6]

The Endocrine Society's 2019 Clinical Practice Guideline on Growth Hormone Deficiency in Adults states: "We recommend using age- and sex-adjusted IGF-1 standard deviation scores to guide dosing of GH therapy, with the target being an IGF-1 within the normal range for age and sex." [7] While that guideline refers to recombinant human GH rather than sermorelin, the IGF-1 monitoring principle applies to sermorelin as well, since sermorelin stimulates endogenous GH secretion and downstream IGF-1 production.

Red Flags for Illegitimate Prescribing

Any website that ships sermorelin without requiring a prescription, or that offers a prescription after only a brief online questionnaire with no lab review, is operating outside the law. The FDA and FTC have both taken enforcement action against peptide vendors selling to consumers without valid prescriptions. [8] Patients in Washington who obtain sermorelin from a research-chemical supplier or an overseas pharmacy are not operating within the legal framework described here, regardless of how the vendor markets the product.

How to Get Sermorelin Legally in Washington: Step-by-Step

Getting sermorelin legally in Washington involves a predictable sequence. No step can be skipped.

Step 1: Order and Review Labs

Order an IGF-1 level, comprehensive metabolic panel, fasting glucose, HbA1c, and a lipid panel. Some clinicians also add a fasting insulin and testosterone (or estradiol for women). These are standard pre-peptide labs and most insurance plans cover basic metabolic and IGF-1 testing with appropriate diagnostic coding.

Step 2: Consult a Qualified Clinician

Book an appointment with a Washington-licensed clinician who has experience with peptide therapy or hormone optimization. Telehealth platforms licensed in Washington can connect you with clinicians who review labs remotely. The consultation must include a review of your symptoms, your lab results, your medical history (particularly any personal or family history of cancer, as active malignancy is a contraindication to sermorelin), and a discussion of risks and benefits.

Step 3: Receive a Patient-Specific Prescription

If the clinician determines sermorelin is appropriate, they issue a patient-specific prescription. Typical adult dosing starts at 0.2 mg subcutaneously each evening before bed, titrated up to 0.3 mg based on IGF-1 response. Some protocols use 5-days-on / 2-days-off cycling to preserve pituitary receptor sensitivity.

Step 4: Fill the Prescription at a Licensed 503A Compounding Pharmacy

Your prescriber or their clinic typically works with one or more partner 503A pharmacies licensed to ship into Washington. The pharmacy contacts the prescriber directly to verify the prescription, compounds the preparation, and ships it to you cold (sermorelin requires refrigeration at 2 to 8 degrees Celsius). Verify that the pharmacy holds a current Washington State out-of-state pharmacy license or is located within Washington.

Step 5: Monitor and Follow Up

A follow-up IGF-1 measurement is typically ordered at 8 to 12 weeks. The target IGF-1 range is generally the mid-normal range for age and sex, not the high end. Supraphysiologic IGF-1 carries theoretical risks including insulin resistance and, over long durations, possible mitogenic effects. [9]

The FDA Bulk Substances Question in Detail

The distinction between 503A and 503B matters more for sermorelin than for many other compounded drugs, and it is worth understanding.

503A vs. 503B: Core Differences

A 503A pharmacy is a traditional compounding pharmacy. It must receive a prescription for an identified individual patient before compounding. It can compound drugs that are not FDA-approved and can use bulk drug substances that are not themselves FDA-approved API, provided those substances meet USP or NF standards or are on the FDA's 503A bulk-drug substances list.

A 503B outsourcing facility can compound larger batches without patient-specific prescriptions and distribute them to hospitals and clinics. To compound a drug product using a bulk substance (rather than from an FDA-approved finished drug), the substance must appear on the FDA's 503B bulks list.

Where Sermorelin Sits

The FDA published its 2019 proposed rule on bulk drug substances for 503B outsourcing facilities and has continued updating it. Sermorelin has been nominated for the 503B bulks list but, as of the 2025 update cycle, FDA has not placed it on the Category 1 list. [3] This means:

• 503B facilities cannot legally compound sermorelin for clinic-stocked vials.
• 503A pharmacies can still compound sermorelin for individual patient prescriptions.
• Patients need a legitimate prescription routed through a 503A pharmacy.

The FDA has been increasingly aggressive about peptides. In 2023 and 2024, the FDA added BPC-157 and several other peptides to lists of substances that cannot be compounded, citing safety concerns. Sermorelin has not been added to those prohibition lists as of this writing, but patients and clinicians should monitor FDA guidance annually. [8]

Clinical Rationale: Why Clinicians Prescribe Sermorelin

Understanding the clinical basis helps explain why a well-trained clinician might choose sermorelin over other GH-axis interventions.

Mechanism of Action

Sermorelin binds to the GHRH receptor on pituitary somatotrophs, stimulating pulsatile release of endogenous growth hormone. Because it works through the pituitary rather than bypassing it (as exogenous recombinant hGH does), it preserves the natural negative-feedback loop: when GH rises, IGF-1 rises, and the pituitary reduces its GH output. This self-limiting mechanism is why many clinicians consider sermorelin to carry a lower risk of IGF-1 overshooting than direct hGH injection. [10]

Evidence Base

The evidence base for sermorelin in adults is smaller than for recombinant hGH but includes several controlled studies. A randomized, double-blind trial by Corpas et al. (N=21, 6 months, 0.5 mg/day sermorelin acetate subcutaneously) published in the Journal of Clinical Endocrinology and Metabolism found statistically significant increases in IGF-1 (P<0.01) and improvements in sleep quality versus placebo in older men with low-normal GH secretion. [11] The absolute effect size on lean body mass was modest (approximately 1.4 kg over 6 months), which aligns with what patients should realistically expect.

A separate analysis in the same journal showed that sermorelin at 2 mcg/kg/day over 6 months in adults with documented adult-onset GHD increased mean IGF-1 SDS from -2.1 to -0.4 (P<0.001), with improvements in quality-of-life scores using the QoL-AGHDA instrument. [12]

Common Off-Label Uses in Washington Clinics

Washington-based clinicians who prescribe sermorelin most often do so for:

• Documented adult GHD (IGF-1 below age-adjusted normal, confirmed with stimulation testing when needed).
• Age-related decline in GH pulsatility (sometimes called somatopause), particularly in patients over 40 with symptoms of fatigue, reduced lean mass, and poor sleep quality.
• Adjunctive therapy alongside TRT or HRT programs where GH-axis optimization is a secondary goal.

Sermorelin is not approved for weight loss, and no randomized controlled trial in a large population supports its use as a primary weight-loss intervention. Patients expecting sermorelin to perform like a GLP-1 agonist on body weight will be disappointed.

Risks, Contraindications, and Safety Monitoring

No drug is without risk. Sermorelin's known adverse effect profile is relatively narrow, but patients and prescribers must be aware of the following.

Known Adverse Effects

The most common adverse effects from the original Geref clinical program were injection-site reactions (redness, swelling, pain), reported in approximately 17% of pediatric patients. In adult compounded-use experience, flushing, headache, and transient dizziness occur in a smaller percentage of users, generally in the first 2 to 4 weeks. Water retention is less pronounced with sermorelin than with exogenous hGH because GH output remains pulsatile rather than sustained.

Contraindications

Clinicians should not prescribe sermorelin to patients with:

• Active malignancy (sermorelin stimulates IGF-1, and IGF-1 is a mitogen).
• Untreated hypothyroidism (adequate thyroid hormone is required for GH-axis function; treat hypothyroidism before initiating sermorelin).
• Pregnancy or breastfeeding (no safety data available).
• Hypersensitivity to GHRH or its analogs.
• Proliferative or severe non-proliferative diabetic retinopathy (a caution carried from the hGH literature).

Patients with controlled type 2 diabetes can often receive sermorelin safely with closer glucose monitoring, but fasting glucose and HbA1c should be checked at baseline and at 3 months.

Laboratory Monitoring Schedule

Most Washington clinicians following best-practice peptide protocols use this monitoring sequence:

• Baseline: IGF-1, CMP, fasting glucose, HbA1c, lipids, thyroid (TSH, free T4).
• 8 to 12 weeks: IGF-1 (to confirm response and avoid supraphysiologic levels).
• Every 6 months thereafter: repeat IGF-1, fasting glucose, HbA1c.
• Annual: comprehensive review including a discussion of continued clinical indication.

Buying Sermorelin "Online" Without a Prescription: Legal Risks

Vendors selling sermorelin as a "research chemical" or "not for human use" operate in a gray market that the FDA has repeatedly signaled it will not tolerate indefinitely. Under the FD&C Act, introducing a misbranded or unapproved new drug into interstate commerce is a federal violation regardless of how the seller labels the product. [8] For the buyer, federal prosecution is rare for small-quantity personal use, but the risks include receiving a product of unknown purity, unknown sterility, and unknown concentration.

A 2020 analysis published in JAMA Internal Medicine found that compounded drugs purchased through non-accredited channels had significantly higher rates of sterility failures and label inaccuracies than those from PCAB-accredited 503A pharmacies. The legal and clinical reasons to use a properly licensed pharmacy are not separable: doing it right protects you medically and legally at the same time.

Telehealth Platforms Serving Washington Patients

Multiple telehealth platforms are licensed to serve Washington State patients for hormone and peptide therapy evaluations. When evaluating a platform, ask these questions directly:

1. Is your prescribing clinician licensed in Washington State?
2. Do you require baseline and follow-up lab work before prescribing?
3. Which 503A compounding pharmacy do you use, and is it PCAB-accredited?
4. Can I view my prescription and have it transferred to a pharmacy of my choice?

A platform that cannot answer all four questions clearly should be treated with caution. The Washington Medical Commission has issued guidance that telehealth prescribing carries the same standard-of-care obligations as in-person prescribing, and clinicians who prescribe peptides without adequate evaluation may face license review. [5]